Person:
BACAKSIZ, AHMET

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
AHMET
Last Name
BACAKSIZ
Name
Email Address
Birth Date

Filters

Browse subject tree
20121
Reset filters

Settings

Rights: info:eu-repo/semantics/openAccess × Subject: Hyperferritinemia ×

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    PublicationMetadata only
    Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?
    (2012-01-01T00:00:00Z) Demirkol, Demet; Yildizdas, Dincer; BAYRAKCİ, BENAN; KARAPINAR, BÜLENT; Kendirli, Tanil; KÖROĞLU, TOLGA FİKRİ; DURSUN, OĞUZ; Erkek, Nilgun; Gedik, Hakan; Citak, Agop; KESİCİ, SELMAN; Karabocuoglu, Metin; Carcillo, Joseph A.; BACAKSIZ, AHMET
    Introduction: Hyperferritinemia is associated with increased mortality in pediatric sepsis, multiple organ dysfunction syndrome (MODS), and critical illness. The International Histiocyte Society has recommended that children with hyperferritinemia and secondary hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) should be treated with the same immunosuppressant/cytotoxic therapies used to treat primary HLH. We hypothesized that patients with hyperferritinemia associated secondary HLH/sepsis/MODS/MAS can be successfully treated with a less immunosuppressant approach than is recommended for primary HLH.